MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.31
-1.12
-10.74%
Closed 16:00 09/21 EDT
OPEN
10.24
PREV CLOSE
10.43
HIGH
10.24
LOW
9.30
VOLUME
898.85K
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
0.7090
MARKET CAP
1.44B
P/E (TTM)
-8.4698
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International Liver Congress (ILC
GlobeNewswire · 08/28 15:30
Adaptimmune Highlights Presentation Of Phase 1 Trial Data With ADP-A2AFP
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(NASDAQ:ADAP), a leader in cell therapy to treat cancer, presented data from its
Benzinga · 08/28 14:35
Enanta Pharma reports encouraging data on HBV and NASH candidates
Data from Enanta Pharmaceuticals' (ENTA) development programs for non-alcoholic steatohepatitis ((NASH)) and hepatitis B virus ((HBV)) will be virtually presented at the European Association for the Study of the Liver Annual
Seekingalpha · 08/28 11:59
The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 12:02
The Week Ahead In Biotech (Aug. 24-29): Lipocine Binary Event, Liver Congress In The Spotlight
After seeing some strength earlier on, biotech stocks came under pressure in the week ended Aug. 21.
Benzinga · 08/23 17:20
Seeking Alpha Catalyst Watch
Seeking Alpha - Article · 08/21 18:56
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 11:51
Adaptimmune EPS beats by $0.20, misses on revenue
Adaptimmune (NASDAQ:ADAP): Q2 GAAP EPS of -$0.04 beats by $0.20. Revenue of $0.5M (+212.5% Y/Y) misses by $0.43M. Shares +1.15% PM. Press Release
seekingalpha · 08/06 16:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADAP stock price target is 12.67 with a high estimate of 17.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 128.32M
% Owned: 83.00%
Shares Outstanding: 154.61M
TypeInstitutionsShares
Increased
18
13.18M
New
51
21.29M
Decreased
11
90.07K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
Chief Executive Officer/Director
Adrian Rawcliffe
Chief Financial Officer
Gavin Wood
Chief Operating Officer
William Bertrand
Vice President/Director of Investor Relations
Sebastien Desprez
Vice President
Paul Stead
Senior Vice President
Elliot Norry
Other
John Lunger
Other
Helen Tayton-Martin
Non-Executive Director
James Noble
Non-Executive Independent Director
Lawrence Alleva
Non-Executive Independent Director
Ali Behbahani
Non-Executive Independent Director
Barbara Duncan
Non-Executive Independent Director
John Furey
Non-Executive Independent Director
Elliott Sigal
Non-Executive Independent Director
Elliot Sigal
Non-Executive Independent Director
Charles Sigal
Non-Executive Independent Director
Tal Zvi Zaks
Non-Executive Independent Director
Tal Zaks
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ADAP stock price target is 12.67 with a high estimate of 17.00 and a low estimate of 9.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADAP
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.